ai
Investment firm partners with AI company to develop new biotechs
Population Health Partners entered an agreement with Edison Scientific to create new biotechnology companies. The firm previously profited from a bidding war over an obesity drug startup.
forbes.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Population Health Partners reached a deal with AI-focused Edison Scientific to launch new biotechnology companies. The agreement follows the firm's involvement in the sale of obesity drug startup Metsera.
Background on the firm The firm is led by a chairman who previously worked as an oncologist and has spent nearly four decades in drug development and biotech investment. It targets large-scale health problems that could generate strong investment returns.
The chairman described the firm's approach as first identifying major health challenges and then seeking technologies, business models, molecules, or diagnostics that could address them.
Recent transaction Metsera received an initial $7.3 billion offer from Pfizer.
Novo Nordisk then submitted an unsolicited $9 billion bid, prompting a $10 billion counteroffer. The chairman said the firm now plans to apply artificial intelligence through the new partnership to repeat similar investment outcomes.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
